Search
Benitec Biopharma Inc
BNTCAdd to Watchlist
13.220USD
+0.530+4.18%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
347.03MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+4.18%
5 Days
+6.87%
1 Month
+19.64%
6 Months
+5.05%
Year to Date
-1.86%
1 Year
+0.38%
Key Figures
12.820Open
13.500High
172.37KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.66%Turnover Ratio
12.690Prev. Close
12.560Low
1.48MTurnover
LossP/E Static
3.71P/B
0.00%Div Yield TTM
-28.43%ROA
17.15052wk High
0.98Volume Ratio
-37.92MNet Profit
26.25MShares
-0.9227EPS TTM
0.28Beta
-29.58%ROE
9.85052wk Low
7.41%Amplitude
100.00%Gross Margin
347.03MMarket Cap
4.13Reward/Risk
3.60%Risk Rate
TradingKey Stock Score of Benitec Biopharma Inc
Currency: USD Updated: 2026-07-02Key Insights
Benitec Biopharma Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 46 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.80.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Benitec Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Benitec Biopharma Inc Highlights
StrengthsRisks
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -14.33, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 33.05M shares, increasing 13.43% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.36K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.40.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
25.800
Target Price
+103.31%
Upside Space
Benitec Biopharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Benitec Biopharma Inc Info
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Ticker SymbolBNTC
CompanyBenitec Biopharma Inc
CEOBanks (Jerel A)
Websitehttps://benitec.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Benitec Biopharma Inc (BNTC)?
The current price of Benitec Biopharma Inc (BNTC) is 13.22.
What is the symbol of Benitec Biopharma Inc?
The ticker symbol of Benitec Biopharma Inc is BNTC.
What is the 52-week high of Benitec Biopharma Inc?
The 52-week high of Benitec Biopharma Inc is 17.15.
What is the 52-week low of Benitec Biopharma Inc?
The 52-week low of Benitec Biopharma Inc is 9.85.
What is the market capitalization of Benitec Biopharma Inc?
The market capitalization of Benitec Biopharma Inc is 347.03M.
Is Benitec Biopharma Inc (BNTC) currently rated as Buy, Hold, or Sell?
According to analysts, Benitec Biopharma Inc (BNTC) has an overall rating of Buy, with a price target of 25.80.
What is the Earnings Per Share (EPS TTM) of Benitec Biopharma Inc (BNTC)?
The Earnings Per Share (EPS TTM) of Benitec Biopharma Inc (BNTC) is -1.05.